Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Investor Presentation (August 2021)
32 slides from Cellectis's investor presentation, August 2021
Slide 1: Commitment To A Cure – Investor Presentation August 2021
Commitment To A Cure Investor Presentation August 2021 cellectis.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking” statements within These forward-looking statements are made in light of the meaning of applicable securities laws, including the Private information currently available to us and are subject to Securities Litigation Reform Act o
Slide 3: Cellectis' Core Assets
Cellectis’ Core Assets Allogeneic CAR-T platform Hematological malignancies and solid tumors HSC platform Genetic disorders (lead asset in sickle cell disease) In-house manufacturing Cells (GMP Raleigh) and starting materials (GMP Paris) Strong partnerships Platform validation and financial upside 3
Slide 4: Cellectis Key Highlights
Cellectis Key Highlights 282 employees 120+ patients dosed 8 clinical trials ongoing & highly experienced 8+ preclinical programs management team and clinical under Cellectis and Cellectis development leadership licensees sponsored trials sponsored by Cellectis or by its licensees 21 years expertise
Slide 5: Cellectis CAR-T Partnerships With Industry Leaders
Cellectis CAR-T Partnerships With Industry Leaders Up To $3.2B In Potential Milestone Payments Plus Royalties Potential economic impact Partner License Territory Most Advanced Targets Status to Cellectis Exclusive license to CD19- Up To $410M In Ex-US Ph1 directed allogeneic CAR T-cells Development
Slide 6: Cellectis Gene Editing Partnerships With Industry Leaders
Cellectis Gene Editing Partnerships With Industry Leaders Leveraging Our TALEN® Platform In Alternative Cellular Approaches Potential economic Partner License Territory Most Advanced Targets Status impact to Cellectis Research collaboration and exclusive license Undisclosed development agreement to
Slide 7: Cellectis' Allogeneic CAR-T Cell Pipeline
Cellectis’ Allogeneic CAR-T Cell Pipeline Product Disease Study Phase 1 Phase 1 Discovery Pre-Clinical Dose Escalation Dose Expansion Pivotal Phase2 UCART22 ACUTE LYMPHOBLASTIC BALLI-01 LEUKEMIA UCART123 ACUTE MYELOID AMELI-01 LEUKEMIA Wholly Owned UCARTCS1 MULTIPLE MELANI-01 MYELOMA B-CELL UCART20x
Slide 8: Cellectis Clinical-Stage UCART Programs
Cellectis Clinical-Stage UCART Programs
Slide 9: Potential Advantages of Allogenic Approach Over Autologous
Potential Advantages of Allogenic Approach Over Autologous “Off-the-shelf” availability Scalable manufacturing Available to patients immediately after treatment decision Reduced manufacturing cost: 100+ doses from one engineering run Dosing flexibility Possibility of redosing 1. 2. T cells from heal
Slide 10: ALLO-501 Clinical Proof-of-Concept from First Licensed Allogeneic CAR-T
ALLO-501 Clinical Proof-of-Concept from First Licensed Allogeneic CAR-T Phase 1 Trial In R/R Non-hodgkin Lymphoma N=41 (LBCL and FL) ALPHA Study Safety – Primary Objective Efficacy – Secondary Objective Allogene plans to § 0% No dose-limiting toxicities OR Graft vs Host § 75% ORR in CAR-T naïve pati
Slide 11: ALLO-715: First Allogeneic BCMA CAR-T in Multiple Myeloma
ALLO-715: First Allogeneic BCMA CAR-T in Multiple Myeloma N=31 (safety Phase 1 dose escalation in population) N=26 (efficacy R/R multiple myeloma Population) UNIVERSAL Study Safety – Primary Objective Efficacy – Secondary Objective § 0% Graft vs Host Disease (GVHD) § 60% Overall Response Rate in the
Slide 12: UCART22 – BALLI-01 Trial Design
UCART22 – BALLI-01 Trial Design Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia Dose Escalation Determine MTD Dose Expansion Arm FC: f
Slide 13: UCART22 – Initial Anti-Leukemic Activity of Wholly-Controlled UCART
UCART22 – Initial Anti-Leukemic Activity of Wholly-Controlled UCART Phase 1 Dose Escalation In R/R Adult N=5 B-acute Lymphoblastic Leukemia BALLI-01 Study Efficacy – Secondary Objective Preliminary data from 5 patients who received UCART22 at DL1 or DL2 Patients at DL1 achieved CRi2 at Day 28; of wh
Slide 14: UCARTCS1 – MELANI-01 Study Schema
UCARTCS1– MELANI-01 Study Schema Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A, Administered in Patients with Relapsed/Refractory Multiple Myeloma Screening LD Treatment Period Follow-up Total N= up to 18 pts ICF UCARTCS1
Slide 15: Clinical Activity Correlated with UCARTCS1A Expansion and Persistence
Clinical Activity Correlated with UCARTCS1A Expansion and Persistence MRD-Neg VGPR M protein D28: BM biopsy 4000 showed MRD- by FACS Serum IgG 3000 analysis M3: BM negative for Serum free lambda LC 2000 MM cells 1000 mg/dL 5 D90: IFE +ve 4 3 2 1 0 Screening D0 D14 D28 M2(D49) M3(D77) D90 UCARTCS1A i
Slide 16: UCART123 – AMELI-01 Trial Design
UCART123 – AMELI-01 Trial Design Phase I, Open Label Dose-escalation And Dose-expansion Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCART123 In Patients With Relapsed/Refractory Acute Myeloid Leukemia Determine Dose Escalation MTD Arm FC: fludarabine (F) + cyclophos
Slide 17: Cellectis Next-Generation UCART Programs
Cellectis Next-Generation UCART Programs
Slide 18: UCART20x22 First Dual-Targeted Allogeneic CAR-T Cell Product Candidate
UCART 20x22 First Dual-Targeted Allogeneic CAR-T Cell Product Candidate CD20-CAR Differentiated MESOTHELINTargets Beyond IS AN CD19 ATTRACTIVE SOLID TUMOR TARGET CD22-CAR § 2 validated targets § Reduced target escape potential § Improved cell killing w CD52 + TCRa KO strengthened synapses Accelerate
Slide 19: UCARTMESO: Allogeneic CAR-T Cell Product Candidate in Solid Tumors
UCARTMESO: Allogeneic CAR-T Cell Product Candidate in Solid Tumors TCR TALEN® KO Graft vs Host rLV Mesothelin is An Attractive Solid Tumor Target Prevention Mesothelin CAR for CAR expression § Tumor-associated antigen broadly TCR overexpressed on various malignant tumor cells TGFβR2 TGFb1 § One of t
Slide 20: UCARTFAP: Targeting Cancer Associated Fibroblasts Using Anti-FAP CAR T-cells
UCARTFAP: Targeting Cancer Associated Fibroblasts (CAFs) Using Anti-FAP CAR T-cells CAFs Play a Central Role For T-cell Exclusion And Immune Suppression In Solid Tumors FAP CAR TCR KO: Graft vs Host TCR § Specific to tumor microenvironment Prevention § Unique surface protein (FAP protein) § High pot
Slide 21: UCARTMUC1 – Next-Gen Product Candidate with Multiple Edits
UCARTMUC1 – Next-Gen Product Candidate with Multiple Edits rLV TCR KO: MUC1 CAR DNTGFβR2 For CAR expression Graft vs Host Prevention TCR TGFBR2 Dominant negative TGFBR2 MHC-I DB2MHLAE B2M KO: Resistance to patient’s DPD1-IL12 3 TALEN® Knock-Outs T-cells 2 Knock-In HLA-E: PD1 Resistance to NK cells T
Slide 22: Gene Therapy: Hematopoietic Stem Cell Platform
GENE THERAPY Hematopoietic Stem Cell Platform
Slide 23: HSC Genome Surgery Platform
HSC Genome Surgery Platform • 75-96% modification efficiency in multiple loci High • >80% cell viability & Clinical-Scale Modification Manufacturing preserve differentiation Efficiency potential • >4-fold increase in primitive HSC Primitive HSC High Cell Viability & • Clinical-scale Potency manufact
Slide 24: Sickle Cell Anemia
Sickle Cell Anemia Genetic origin Gene therapy treatment Normal HBB (β) Sickle HBB (βs) Sickle HBB βs GAG GTG Eliminate GTG Glutamate Valine (HbA) (HbS) TALEN® .HEAL HbA HbS GAG DNA template Corrected HBB β P24 GAG Repair Normal RBC 24
Slide 25: .HEAL Gene Surgery To Cure Sickle Cell Disease – TALGlobin01
.HEAL Gene Surgery To Cure Sickle Cell Disease – TALGlobin01 SCA HBB surgery repairs hemoglobin and brings it back to its physiological level • Highly efficient correction of sickle HBB gene • Hemoglobin rescued to therapeutic level • Selection free process • Low β0 collateral effect mitigates poten
Slide 26: .HEAL Pipeline – Fully-owned By Cellectis
.HEAL Pipeline – Fully-owned By Cellectis HSC Genome Surgery For Multiple Genetic Diseases Indications Cell Type Candidate Target Discovery Preclinical IND- enabling Sickle Cell Anemia CD34+ TALGlobin-01 HBB Lysosomal Storage CD34+ TalX-05 Undisclosed Disease Primary T-Cell TalX-03 STAT3 Immunodefic
Slide 27: Cellectis In-House GMP Manufacturing Facilities
Cellectis In-House GMP Manufacturing Facilities
Slide 28: Fully Integrated cGMP Platform
Fully Integrated cGMP Platform ALPHA Study Paris Raleigh, North Carolina Paris, France UCART – Clinical & Commercial Starting Materials – Clinical 82,000 sq ft. facility 14,000 sq ft. facility ü Cell therapy manufacturing suites ü Nucleic acid & vector manufacturing suites ü QC labs ü QC labs ü Ware
Slide 29: UCART Manufacturing
UCART Manufacturing 9 years of experience in allogeneic CAR-T manufacturing Thawed Frozen leukopaks Lentivector TALEN®-mediated gene peripheral blood transduction editing mononuclear cells 1 2 3 4 Cell expansion Purification Fill & finish Frozen UCART products 5 6 7 8 29
Slide 30: Cellectis Upcoming Milestones
Cellectis Upcoming Milestones
Slide 31: Upcoming Expected Milestones
Upcoming Expected Milestones Clinical Validation • Enrollment of patients in phase 1 studies to establish optimal dose and lymphodepletion regimen for UCART22, CS1 and 123 • Initiation of a potentially pivotal trial of ALLO-501A (licensed) expected by end 2021 • Enrollment of patients in phase 1 stu
Slide 32: Thank You
THANK YOU Reach us at: investor@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 430 East 29th Street 2500 Sumner Boulevard 75013 Paris – France 10016 New York, NY – USA 27616 Raleigh, NC – USA 32